Top Story Today
The Bargain-Bin Pfizer Drug That Just Made Celcuity a $6 Billion Company
Celcuity paid Pfizer roughly $10 million in 2021 for a shelved cancer drug. The FDA just approved it, branded REVTORPYK, for HR-positive, HER2-negative metastatic breast cancer, and the company is now worth roughly $6 billion. The Phase 3 trial showed a 76% reduction in the risk of disease progression: median progression-free survival of 9.3 months versus just 2.0 months for the comparator. It's the first-ever approved PI3K/mTOR dual inhibitor, and unlike rival drugs that only work in the 40% of patients with a specific mutation, gedatolisib covers a broader population. Every analyst covering the stock rates it a Buy, and the acquisition math practically does itself.
Why it matters: This approval gives oncologists a genuinely new weapon against endocrine-resistant breast cancer, a setting where patients have long been shuffled toward chemotherapy for lack of better options. It also transforms Celcuity into a textbook acquisition target: single blockbuster asset, mid-cap valuation, massive market, and a commercial launch that any Big Pharma sales force could supercharge overnight.
Read more →Clinical and Regulatory
Biogen's Alzheimer's Drug Missed Its Test. They're Going to Phase 3 Anyway.
Biogen's anti-tau Alzheimer's drug diranersen missed its primary endpoint, but the lowest dose slowed cognitive decline by 26% on the key dementia scale and cut tau protein levels by 50 to 65%. The stock dropped 6 to 8%, yet Biogen is pressing ahead to Phase 3. If it works, it would validate an entirely new therapeutic strategy for a disease affecting tens of millions worldwide.
Read more →The FDA Just Wrote a Rulebook for Tripping
The FDA finalized its guidance on psychedelic clinical trials, covering everything from blinding strategies to a mandatory two-monitor buddy system during dosing sessions. The rules read like a point-by-point response to the MDMA rejection that rocked Lykos in 2024. Compass Pathways, the frontrunner with two positive Phase 3 trials, could have the first approved classic psychedelic on the market by early 2027.
Read more →An Ebola Pill Gets Its First Real Test During an Active Outbreak
Congo started enrolling patients in a trial of Gilead's oral antiviral obeldesivir as post-exposure prevention during a Bundibugyo Ebola outbreak that has killed over 700 people. No treatments exist for this Ebola species. In primate studies, the pill delivered 100% survival in rhesus macaques. If it works in humans, it could become standard equipment in the outbreak response toolkit.
Read more →Deals and Manufacturing
A $2.5 Billion AI Deal That Isn't About Drug Discovery
Insilico Medicine and Taiwan's Bora Pharmaceuticals announced a strategic alliance worth up to $2.5 billion, but it's not about finding new drugs. Insilico will embed its AI platform into Bora's manufacturing facilities to optimize production, quality control, and supply chains. The $2.5 billion is a theoretical ceiling (no upfront payment disclosed), but it signals AI's expansion from the lab bench to the factory floor.
Read more →The FDA Wants to Let Hospitals Build Their Own Drug Factories
The FDA proposed a new regulatory category called the "distributed manufacturing establishment," allowing networks of modular drug production units to register as a single facility. For cell and gene therapies, where each dose is custom-built from a patient's own cells and shipped cross-country, this is the foundation for near-patient manufacturing that could cut wait times from weeks to days.
Read more →Funding and Financings
A Three-Year-Old Biotech Wants to Take On Dupixent's Multibillion-Dollar Empire
Attovia Therapeutics filed for a $100 million IPO with plans to challenge Dupixent using miniaturized antibodies that could enable quarterly dosing (versus Dupixent's biweekly shots). The kicker: Sanofi's own venture arm invested in Attovia's Series C. The company has $255 million in venture backing but zero approved products, making this a pure bet on platform science against a proven juggernaut.
Read more →